{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:55:57Z","timestamp":1784548557325,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.taap.2019.03.016","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T20:13:03Z","timestamp":1553199183000},"page":"154-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Pharmacology, toxicology and clinical safety of glycopyrrolate"],"prefix":"10.1016","volume":"370","author":[{"given":"Monika","family":"Chabicovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-9901","authenticated-orcid":false,"given":"Michael","family":"Soeberdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Masur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.03.016_bb0005","series-title":"Statement on a nonproprietary name adopted by the USAN council","author":"(CD-92), U","year":"2015"},{"key":"10.1016\/j.taap.2019.03.016_bb0010","series-title":"Statement on a nonproprietary name adopted by the USAN council","author":"(cd-93), U","year":"2015"},{"key":"10.1016\/j.taap.2019.03.016_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.016_bb0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-6576.1993.tb03780.x","article-title":"Pharmacokinetics and related pharmacodynamics of anticholinergic drugs","volume":"37","author":"Ali-Melkkila","year":"1993","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.taap.2019.03.016_bb0025","series-title":"Botox (onabotulinumtoxinA) prescribing information","author":"Allergan","year":"2019"},{"key":"10.1016\/j.taap.2019.03.016_bb0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/(SICI)1096-9136(199605)13:5<493::AID-DIA62>3.0.CO;2-Q","article-title":"Treatment of diabetic gustatory sweating with topical glycopyrrolate cream","volume":"13","author":"Atkin","year":"1996","journal-title":"Diabetic Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/000992289803700805","article-title":"Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy","volume":"37","author":"Bachrach","year":"1998","journal-title":"Clin. Pediatr."},{"key":"10.1016\/j.taap.2019.03.016_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2133.2007.07884.x","article-title":"Use of oral glycopyrronium bromide in hyperhidrosis","volume":"157","author":"Bajaj","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.taap.2019.03.016_bb0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drudis.2017.10.015","article-title":"Indacaterol\/glycopyrronium: a dual bronchodilator for COPD","volume":"23","author":"Banerji","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2019.03.016_bb0050","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.taap.2019.03.016_bb0055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/archpedi.1996.02170340046009","article-title":"Glycopyrrolate treatment of chronic drooling","volume":"150","author":"Blasco","year":"1996","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0060","author":"Brickell"},{"key":"10.1016\/j.taap.2019.03.016_bb0065","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor","year":"2012","journal-title":"CNS Neurosci. Therap."},{"key":"10.1016\/j.taap.2019.03.016_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study","volume":"14","author":"Chapman","year":"2014","journal-title":"BMC Pulmon. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/resp.13100","article-title":"Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Chen","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.taap.2019.03.016_bb0085","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jdv.14081","article-title":"Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review","volume":"31","author":"Cruddas","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.taap.2019.03.016_bb0090","first-page":"147","article-title":"The action of certain esters and ethers of choline and their relation to muscarine","volume":"6","author":"Dale","year":"1914","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1465-9921-12-156","article-title":"Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial","volume":"12","author":"D'Urzo","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.taap.2019.03.016_bb0100","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2147\/COPD.S81266","article-title":"Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data","volume":"10","author":"D'Urzo","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.taap.2019.03.016_bb0105","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/COPD.S113306","article-title":"New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate\/formoterol combination formulated by co-suspension delivery technology","volume":"13","author":"D'Urzo","year":"2018","journal-title":"Int. J. Chronic Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.taap.2019.03.016_bb0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-018-0084-8","article-title":"Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials","volume":"28","author":"D'Urzo","year":"2018","journal-title":"NPJ Prim. Care Respirat. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-3-642-23274-9_15","article-title":"Muscarinic agonists and antagonists: effects on gastrointestinal function","author":"Ehlert","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.016_bb0120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clinthera.2012.02.026","article-title":"Glycopyrrolate for chronic drooling in children","volume":"34","author":"Eiland","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0125","series-title":"European Medicines Agency: EMEA\/H\/C\/002430 - Assessment report Seebri Breezhaler","author":"EMA","year":"2012"},{"key":"10.1016\/j.taap.2019.03.016_bb0130","series-title":"European Medicines Agency: EMEA\/H\/C\/003883\/0000 - Assessment report Sialanar","author":"EMA","year":"2016"},{"key":"10.1016\/j.taap.2019.03.016_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/NDT.S14028","article-title":"Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children","volume":"7","author":"Evatt","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.taap.2019.03.016_bb0140","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0145","series-title":"7highlights of prescribing information xeomin (incobotulinumtoxina) for injection, intramuscular use","author":"FDA","year":"2010"},{"key":"10.1016\/j.taap.2019.03.016_bb0150","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0155","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0160","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0165","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0170","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0175","author":"FDA"},{"key":"10.1016\/j.taap.2019.03.016_bb0180","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1096\/fasebj.9.8.7768353","article-title":"Muscarinic acetylcholine receptors: signal transduction through multiple effectors","volume":"9","author":"Felder","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.taap.2019.03.016_bb0185","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1021\/jm990607u","article-title":"Therapeutic opportunities for muscarinic receptors in the central nervous system","volume":"43","author":"Felder","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2019.03.016_bb0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.15326\/jcopdf.6.1.2018.0146","article-title":"Efficacy and safety of nebulized Glycopyrrolate\/eFlow\u00ae closed system in patients with moderate-to-very-severe chronic obstructive pulmonary disease with pre-existing cardiovascular risk factors","volume":"6","author":"Ferguson","year":"2019","journal-title":"Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.taap.2019.03.016_bb0195","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease","volume":"73","author":"Fox","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2019.03.016_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/jm50012a004","article-title":"Derivatives of 3-pyrrolidinols\u2014III. The chemistry, pharmacology, and toxicology of some N-substituted-3-pyrrolidyl \u03b1-substitutes phenylacetates","volume":"2","author":"Franko","year":"1960","journal-title":"J. Med. Pharm. Chem."},{"key":"10.1016\/j.taap.2019.03.016_bb0205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1749-6632.1962.tb45296.x","article-title":"Pharmacodynamic evaluation of glycopyrrolate in animals","volume":"99","author":"Franko","year":"1962","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2019.03.016_bb0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0041-008X(70)90193-6","article-title":"A condensed format for reporting toxicologic data\u2014results of studies on glycopyrrolate","volume":"17","author":"Franko","year":"1970","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.016_bb0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/11208120-000000000-00000","article-title":"Glycopyrrolate Oral solution","volume":"14","author":"Garnock-Jones","year":"2012","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.taap.2019.03.016_bb0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/11208120-000000000-00000","article-title":"Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions","volume":"14","author":"Garnock-Jones","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.taap.2019.03.016_bb0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pupt.2014.05.005","article-title":"The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide","volume":"28","author":"Gavalda","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.taap.2019.03.016_bb0230","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","article-title":"Topical Glycopyrronium Tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","volume":"80","author":"Glaser","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.taap.2019.03.016_bb0235","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2183\/pjab.89.226","article-title":"Molecular properties of muscarinic acetylcholine receptors","volume":"89","author":"Haga","year":"2013","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.taap.2019.03.016_bb0240","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0196-0644(94)70329-9","article-title":"Acute angle-closure glaucoma as a complication of combined \u03b2-agonist and ipratropium bromide therapy in the emergency department","volume":"23","author":"Hall","year":"1994","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0245","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1288\/00005537-197811000-00010","article-title":"The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent","volume":"88","author":"Hays","year":"1978","journal-title":"Laryngoscope"},{"key":"10.1016\/j.taap.2019.03.016_bb0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/019459988209000410","article-title":"The Frey syndrome: a simple, effective treatment","volume":"90","author":"Hays","year":"1982","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.taap.2019.03.016_bb0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.1984.tb04653.x","article-title":"Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution","volume":"110","author":"H\u00f6lzle","year":"1984","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.taap.2019.03.016_bb0260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14740338.2017.1354983","article-title":"Safety of available and emerging drug therapies for hyperhidrosis","volume":"16","author":"Hosp","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.taap.2019.03.016_bb0265","first-page":"17","article-title":"The antidepressant effects of anticholinergic drugs","volume":"47","author":"Howland","year":"2009","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.taap.2019.03.016_bb0270","series-title":"Structure and activation of muscarinic acetylcholine receptors","author":"Hulme","year":"2003"},{"key":"10.1016\/j.taap.2019.03.016_bb0275","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jdv.12518","article-title":"Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study","volume":"29","author":"Hyun","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.taap.2019.03.016_bb0280","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.taap.2019.03.016_bb0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3349\/ymj.2003.44.4.579","article-title":"Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate","volume":"44","author":"Kim","year":"2003","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.taap.2019.03.016_bb0290","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2133.2008.08476.x","article-title":"Topical glycopyrrolate for patients with facial hyperhidrosis","volume":"158","author":"Kim","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.taap.2019.03.016_bb0295","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/bja\/71.3.437","article-title":"Pharmacokinetics of glycopyrronium in uraemic patients","volume":"71","author":"Kirvela","year":"1993","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.taap.2019.03.016_bb0300","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.03.015","article-title":"Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3)","volume":"115","author":"Mahler","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hed.2880110115","article-title":"Frey's syndrome: treatment with topical glycopyrrolate","volume":"11","author":"May","year":"1989","journal-title":"Head Neck"},{"key":"10.1016\/j.taap.2019.03.016_bb0315","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/jcph.536","article-title":"Pharmacometrics-guided drug development of antihyperhidrosis agents","volume":"55","author":"Mehrotra","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.016_bb0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-pharmtox-010814-124536","article-title":"Therapeutic modulation of urinary bladder function: multiple targets at multiple levels","volume":"55","author":"Michel","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2019.03.016_bb0325","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/archpedi.154.12.1214","article-title":"Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study","volume":"154","author":"Mier","year":"2000","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/014107680009300903","article-title":"Anticholinergic side-effects of drugs in elderly people","volume":"93","author":"Mintzer","year":"2000","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0335","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0306-3623(81)90064-1","article-title":"Glycopyrrolate","volume":"12","author":"Mirakhur","year":"1981","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.016_bb0340","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1073\/pnas.97.12.6245","article-title":"A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away","volume":"97","author":"Nathanson","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.taap.2019.03.016_bb0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.taap.2019.03.016_bb0350","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ucl.2016.04.004","article-title":"Antimuscarinics, beta-3 agonists, and Phosphodiesterase inhibitors in the treatment of male lower urinary tract symptoms: an evolving paradigm","volume":"43","author":"Osman","year":"2016","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.taap.2019.03.016_bb0355","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/1060028017705149","article-title":"Role of long-acting muscarinic antagonist\/long-acting beta2-agonist therapy in chronic obstructive pulmonary disease","volume":"51","author":"Petite","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.taap.2019.03.016_bb0360","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/COPD.S67758","article-title":"Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD","volume":"10","author":"Prakash","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.taap.2019.03.016_bb0365","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00000542-197805000-00007","article-title":"Comparative penetration of glycopyrrolate and atropine across the blood--brain and placental barriers in anesthetized dogs","volume":"48","author":"Proakis","year":"1978","journal-title":"Anesthesiology"},{"key":"10.1016\/j.taap.2019.03.016_bb0370","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0773.1998.tb01456.x","article-title":"Pharmacokinetics and oral bioavailability of glycopyrrolate in children","volume":"83","author":"Rautakorpi","year":"1998","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2019.03.016_bb0375","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.2147\/DDDT.S135377","article-title":"Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Santus","year":"2017","journal-title":"Drug Des. Devel. Therapy"},{"key":"10.1016\/j.taap.2019.03.016_bb0380","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0091-6749(88)90060-7","article-title":"Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate","volume":"82","author":"Schroeckenstein","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.taap.2019.03.016_bb0385","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CP201612","article-title":"Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)","volume":"50","author":"Sechaud","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0390","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13318-015-0300-7","article-title":"Pharmacokinetics of Glycopyrronium following repeated once-daily inhalation in healthy Chinese subjects","volume":"41","author":"Sechaud","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.taap.2019.03.016_bb0395","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-1754.1997.tb00991.x","article-title":"Preliminary study of glycopyrrolate in the management of drooling","volume":"33","author":"Stern","year":"1997","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.taap.2019.03.016_bb0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","article-title":"The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium","volume":"343","author":"Sykes","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0163-7258(03)00032-9","article-title":"Regulation of muscarinic acetylcholine receptor signaling","volume":"98","author":"van Koppen","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.03.016_bb0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2011.01.023","article-title":"Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine","volume":"66","author":"Walling","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.taap.2019.03.016_bb0415","first-page":"57","article-title":"Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.taap.2019.03.016_bb0420","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.taap.2019.03.016_bb0425","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2019.03.016_bb0430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000449390","article-title":"The efficacy of Antimuscarinics alone or in combination with alpha-blockers for the treatment of ureteral stent-related symptoms: a systematic review and meta-analysis","volume":"99","author":"Yan","year":"2017","journal-title":"Urol. Int."},{"key":"10.1016\/j.taap.2019.03.016_bb0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/TCRM.S27362","article-title":"Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions","volume":"8","author":"Zeller","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.taap.2019.03.016_bb0440","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/TCRM.S26893","article-title":"Randomized phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions","volume":"8","author":"Zeller","year":"2012","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T08:34:48Z","timestamp":1576830888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19301061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":88,"alternative-id":["S0041008X19301061"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.016","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology, toxicology and clinical safety of glycopyrrolate","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}